Equities

United Laboratories International Holdings Ltd

United Laboratories International Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.25
  • Today's Change0.00 / 0.00%
  • Shares traded13.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 18 2024 14:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year United Laboratories International Holdings Ltd grew revenues 21.22% from 11.33bn to 13.74bn while net income improved 70.85% from 1.58bn to 2.70bn.
Gross margin46.15%
Net profit margin20.75%
Operating margin26.32%
Return on assets13.65%
Return on equity23.21%
Return on investment20.72%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at United Laboratories International Holdings Ltd fell by 481.08m. However, the company earned 2.44bn from its operations for a Cash Flow Margin of 17.75%. In addition the company used 1.56bn on investing activities and also paid 1.36bn in financing cash flows.
Cash flow per share2.06
Price/Cash flow per share4.92
Book value per share8.02
Tangible book value per share7.93
More ▼

Balance sheet in CNYView more

United Laboratories International Holdings Ltd has a Debt to Total Capital ratio of 15.32%, a higher figure than the previous year's 7.67%.
Current ratio2.04
Quick ratio1.72
Total debt/total equity0.1816
Total debt/total capital0.1532
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)3.64%
Div growth rate (5 year)46.04%
Payout ratio (TTM)34.99%
EPS growth(5 years)35.74
EPS (TTM) vs
TTM 1 year ago
30.07
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.